Core Viewpoint - Longkun Technology reported a stable performance in its 2024 annual report, with total revenue of 1.791 billion yuan, a year-on-year increase of 2.18%, and a net profit attributable to shareholders of 216 million yuan, up 20.51% year-on-year. However, the bioenergy segment faced challenges due to an EU anti-dumping investigation, resulting in a 19.41% decline in revenue from this segment. The company is focusing on technological innovation and market expansion to mitigate these challenges and is accelerating its layout in synthetic biology manufacturing to capture a larger market share in the green economy and health industry [1][4][7]. Group 1: Biomass Resource Recycling Business - Longkun Technology has secured multiple significant projects in the biomass resource recycling sector, including a 25.5023 million yuan project in Beijing and a 1.654 billion yuan project in Tongzhou District, which has a processing capacity of 2,100 tons per day and a concession period of 40 years [4]. - Despite the success in project bidding, the bioenergy business has been impacted by the EU's anti-dumping investigation, which imposed a temporary anti-dumping tax of 23.7%, leading to a 19.41% decline in bioenergy revenue [4][6]. - The management indicated that the profit from the biodiesel business primarily comes from self-produced low-cost raw oil, suggesting that market changes have a limited impact on overall operations [4]. Group 2: Synthetic Biology Manufacturing Business - Longkun Technology is actively developing the human milk oligosaccharides (HMOs) sector, collaborating with institutions like the Hefei Institute of Physical Science to advance products such as LNT and LNnT [5][6]. - The company has made significant progress in product certification and market access, with LNnT receiving approval as a new food additive from the National Health Commission and 2'-FL obtaining Self-GRAS certification from the FDA [6][7]. - The establishment of a 1,000-ton HMO production base is underway, with the first phase expected to begin trial production in the first half of 2025 [6]. Group 3: Profit Model - Longkun Technology's profit model is diversified, comprising biomass resource recycling and synthetic biology manufacturing. The company utilizes BOT and BOO models to charge waste treatment fees and sell biodiesel and green electricity [7]. - In 2024, engineering construction revenue surged by 137.82% to 418 million yuan, while operational service revenue increased by 8.57% to 581 million yuan, indicating stable growth despite the decline in bioenergy revenue [7]. - The synthetic biology manufacturing segment is expected to become a new profit growth point as products gain market access, contributing to a 32.07% year-on-year increase in non-net profit [7].

截至2025年4月30日收盘，星湖科技(600866)报收于7.56元，下跌1.05%，换手率3.45%，成交量38.24万 手，成交额2.92亿元。 董秘最新回复 投资者： 去年请问出口美国收入多少？ 董秘： 尊敬的投资者，您好！在国际市场上，公司产品远销欧洲、东南亚、韩国等50多个国家与地 区，公司2024年度国外整体销售收入情况请详见公司于2025年4月22日在上海证券交易所披露的临2025- 011号《2024年度主要经营数据公告》。感谢您的关注！ 投资者： 请问，截止4月25日收盘，股东户数多少？ 董秘： 尊敬的投资者，您好！关于公司的股东户数请详见公司于2025年4月22日在上海证券交易所披露 的《2025年第一季度报告》，感谢您的关注！ 投资者： 董秘您好，根据美国对中国的最新关税政策，对公司影响有多大，是否可以进行成本转移， 公司对美国出口的营业收入占比有多少，未来对美业务规划如何。 董秘： 尊敬的投资者，您好！在国际市场上，公司产品远销欧洲、东南亚、韩国等50多个国家与地 区，目前美国对中国的关税政策不会对公司的生产经营产生重大影响。公司将密切关注国际经济环境及 相关政策的变化，积极研究和制 ...

证券研究报告·公司点评报告·化学制药 科伦药业（002422） 2025 年一季报点评：高基数扰动 Q1，创新管 线兑现+国际化打开长期空间 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 21,454 | 21,812 | 25,300 | 27,822 | 30,605 | | 同比（%） | 12.69 | 1.67 | 15.99 | 9.97 | 10.00 | | 归母净利润（百万元） | 2,456 | 2,936 | 3,534 | 4,241 | 4,675 | | 同比（%） | 44.03 | 19.53 | 20.37 | 20.01 | 10.23 | | EPS-最新摊薄（元/股） | 1.54 | 1.84 | 2.21 | 2.65 | 2.93 | | P/E（现价&最新摊薄） | 23.56 | 19.71 | 16.37 | 13.64 | 12.38 | [Table_Ta ...

作为新质生产力的代表，合成生物学、生物制造以及生物产业，近些年，受到来自政产学研用金各 方广泛关注和重点支持，多地政府将合成生物制造产业写进工作报告。 科学家、企业家和投资家， 在产业发展中发挥着重要作用。 融行业智慧、共襄盛举 扫码！锁定免费参会名额！ 话题将覆盖： 农业、食品与能源， 医美、医药、大健康 ， 合成生物技术、中试放大与商业化， 以 及 项目路演 等多个方面，诚邀莅临，共襄盛举！ 往期精彩： 聚产业力量、擘画未来 第三届SynBio Suzhou中国合成生物学"科学家+企业家+投资家"大会 将于2025年8月1-2日在 苏州 国际博览中心 举办（同期举办 第七届CMC-China博览会 ）！ 圆满落幕！下一站去哪？2023中国（苏州）合成生物学创新峰会成功举办 2023中国(苏州)合成生物学产业技术峰会圆满落幕 合成生物，聚势苏州：2024中国合成生物学"科学家+企业家+投资家"大会圆满召开！ 大会主办丨 Synbio深波 会议时间 | 2025年8月1-2日 会议地点 | 中国·苏州·国际博览中心B馆 扫码！锁定免费参会名额！ 往期嘉宾 阵容 (按首字母排序,排名不分先后，嘉宾单位或头衔为参 ...

Solena 将利用这笔投资，从位于帝国理工学院白城深度科技园区的 I-HUB 大楼搬迁至更大的工厂，并 力求与帝国理工学院保持密切联系。这将使该公司能够与知名时尚品牌合作，扩大其新型纺织纤维的生 产规模。 声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作新材料相关领域介绍，本文不构成任何投资建 议！转载请注明来源！ 近日，英国合成生物学公司 Solena Materials 宣布了670万美元的种子融资，该公司利用 新型蛋白质 纤维开发新一代可持续高性能纺织品 ，本轮资金将用于大规模生产 蛋白质纤维 。 本轮融资由大卫·哈丁爵士以及 SynBioVen 和 Insempra（德国合成生物学公司，主要产品为脂质等） 共同参与。 Solena 的联合创始人兼首席执行官James MacDonald 博士在帝国理工学院担任研究员期间，与其他联 合创始人合作开发了该公司背后的技术。" 我们正在利用人工智能创建自然界中不存在的蛋白质序列， 使其既具备我们所需的性能规格，又具有高度的可制造性 ，"他解释道。 Solena 于 2022 年成立，并在当年获得 Insempra 360 万欧元的 ...

证券研究报告·公司点评报告·化学制药 科伦药业（002422） 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 21,454 | 21,812 | 25,300 | 27,822 | 30,605 | | 同比（%） | 12.69 | 1.67 | 15.99 | 9.97 | 10.00 | | 归母净利润（百万元） | 2,456 | 2,936 | 3,534 | 4,241 | 4,675 | | 同比（%） | 44.03 | 19.53 | 20.37 | 20.01 | 10.23 | | EPS-最新摊薄（元/股） | 1.54 | 1.84 | 2.21 | 2.65 | 2.93 | | P/E（现价&最新摊薄） | 23.56 | 19.71 | 16.37 | 13.64 | 12.38 | [Table_Tag] [Table_Summary] 投资要点 2025 年 05 月 05 ...

Financial Data and Key Metrics Changes - For the second quarter of fiscal 2025, the company reported record revenue of $92.8 million, an increase of 23% year over year and 4.6% sequentially [13][24] - Gross margin for the quarter was 49.6%, up from 41% in the same quarter of fiscal 2024, reflecting improved operational efficiency [13][29] - Adjusted EBITDA loss was approximately $14.8 million, an improvement of about $11.9 million compared to the second quarter of fiscal 2024 [30] Business Line Data and Key Metrics Changes - Revenue from Synbio increased to $36 million, a growth of 21% year over year [13][24] - NGS revenue grew to approximately $51.1 million, an increase of 25% year over year [16][25] - Biopharma services revenue was $5.7 million, reflecting a growth of 21% year over year [16][25] Market Data and Key Metrics Changes - Healthcare revenue rose to $52.8 million, up 29% year over year [26] - Industrial chemical revenue increased to $22.8 million, a 12% rise from the previous year [26] - Academic revenue was $16.5 million, up 20% year over year [27] Company Strategy and Development Direction - The company has spun out DNA Data Storage as an independent entity, Atlas Data Storage, to focus on commercialization and drive success [9][11] - The strategy emphasizes operational agility and customer engagement to maintain competitive positioning [18][19] - The company aims to achieve adjusted EBITDA breakeven by the end of fiscal 2026, with a focus on innovation and market share growth [34][35] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong order bookings exceeding $100 million in the last two quarters [38] - The company is prepared to navigate market volatility and leverage it as an opportunity for growth [36][38] - Management acknowledged challenges in the academic sector but remains confident in the value proposition of their products [72][74] Other Important Information - The company ended the quarter with cash, cash equivalents, and short-term investments of approximately $257.1 million [31] - The company expects gross margin improvements to exceed 50% in the latter half of the fiscal year [34] Q&A Session Summary Question: Impact of tariffs on guidance and demand from competitors - Management indicated that they have accounted for potential tariff impacts in their guidance and noted strong share gains despite macro challenges [40][42] Question: Effect of promotions on academic market growth - Management confirmed that the 20% growth in the academic market was partly due to promotional activities, which they plan to continue until the end of the fiscal year [47][50] Question: Guidance for NGS revenue from top customers - Management expects growth from both existing and new customers, with top customers growing at a rate similar to the overall NGS business [53][54] Question: Reinvestment of savings from the spin-off into R&D - Management confirmed that savings from the spin-off will be partially reinvested into higher priority R&D initiatives [56][61] Question: Academic market's importance and growth assumptions - Management highlighted a significant opportunity in the academic market, with expectations for continued growth despite budget constraints [83][84]

投资者关系 活动类别 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他 参与单位名称 及人员姓名 中信证券、中金公司、华创证券、华安证券等 25 家机构 33 位投资者， 部分名单详见附件清单。 重要提示：参会人员名单由组织机构提供并经整理后展示。公司无法保 证参会人员及其单位名称的完整性、准确性，请投资者注意。 时间 2025 年 4 月 30 日（周三）15:00-16:00 方式 电话会议 上市公司接待 人员姓名 副董事长：张立忠先生 董事、总裁：谈松林先生 董事：邵丽君女士 财务总监：姜晗女士 董事会秘书：尹伟先生 创种科技副总裁：李军民女士 证券代码：002385 证券简称：大北农 北京大北农科技集团股份有限公司 投资者关系活动记录表 编号： 2025-001 | | 一、2024 年整体情况概览 | | --- | --- | | | 1、营收利润方面 | | | 2024 年，公司实现营业收入 287.67 亿元，其中：饲料产品收入 190.54 | | | 亿元，占营收比重为 66.24%；控股公司生猪产品收入 亿元，占营收比 62.78 | | | 重为 ...

Group 1 - During the "May Day" holiday, construction workers in Shandong are actively working on key projects to ensure progress [1][2] - A 240-meter super high-rise complex is under construction in Qingdao, which aims to attract more shipping, trade, and financial enterprises [2] - The construction team is collaborating with Qingdao University of Technology to tackle the complex structural challenges of the project using BIM modeling and stress simulation [2][4] Group 2 - The Dongxiao Biological High-end Intelligent Health Deep Processing Project includes the construction of multiple production lines with a total capacity of 120,000 tons [3] - The project aims to produce various products, including dietary fiber and probiotics, to meet diverse customer needs [3] - The construction of the Fuxing Road project in Zaozhuang High-tech Zone is progressing, with 85% of the overall work completed [4] Group 3 - Advanced technology is being utilized on construction sites, including AI cameras and smart inspection robots, to enhance safety and efficiency [4] - The Qingdao project has introduced a "Worker Technology Service Station" for safety training, utilizing VR technology for immersive learning experiences [4]

Core Viewpoint - Synthetic biology is rapidly transforming various aspects of life, including healthcare, energy, and food production, driven by interdisciplinary research and innovation in biological engineering [1][3]. Group 1: Industry Development - The field of synthetic biology and biomanufacturing aims to design and modify biological systems to address challenges in materials, food, energy, environment, and health [1]. - In 2022, the National Development and Reform Commission emphasized the promotion of synthetic biology technology innovation in the "14th Five-Year Plan for Bioeconomic Development" [3]. - The establishment of the Synthetic Biology and Biomanufacturing Institute at Tianjin University aims to respond to the challenges of the biotechnology revolution and train innovative talents in this field [5]. Group 2: Research and Innovations - Researcher Sun Yuanxia has developed a sugar bioconversion synthesis platform, achieving a breakthrough in the precise total synthesis of rare sugars from carbon dioxide, significantly reducing resource dependency and production time from years to hours [2]. - Tianjin University's research team has utilized synthetic biology strategies to produce rare ginsenosides, known for their high bioactivity and health benefits, providing a new approach for efficient production [5]. - The advancements in biological engineering are expected to lower production costs and enhance accessibility to beneficial compounds like rare ginsenosides for the general public [5].